Apparently, trade sale valuations for medical device companies...

Apparently, trade sale valuations for medical device companies generally range between 2xs to 3xs revenues. AHZ revenues have a large, non-proprietary component (infusions business) putting a damp on valuation, while the Adapt technology sales growth and potential attract a premium. AHZ's valuation is complicated by its 72% interest in AHZ Vaccines. As WP stated there would be no more AHZ $s going to vaccines, then one assumes AHZ's interest will be diluted down the track; after spending $13.5 million there thus far with no guarantee of a ROI, let alone sunk dollars, as it's still early days in expensive R&D demands before a commercial return. Using a generous 3xs revenue multiplier, a case could be made for a $75m to $90 million market cap on potential FY18 revenues (about 30 to 35 cents a share). Perhaps, add on $.05 a share for the immune division. This calculus may not appeal to the cheer squad but at 26 to 27 cents a share, AHZ looks very good value to risk especially considering the market always misprices at extremis in overvaluation and undervaluation as appears to be the case now.